AUS
NZ
UK
CA
USA
IND
Highlights
European indices, including the FTSE 100 and DAX, moved higher following a US-China tariff de-escalation agreement.
The pharmaceutical sector weighed on the FTSE 100, with AstraZeneca, Hikma Pharmaceuticals, and GSK declining.
Broader European markets, such as France’s CAC 40 and Germany’s DAX, posted stronger intraday gains.
European equity markets, including those tracked by the FTSE 100 (INDEXFTSE: UKX), FTSE 350, and Germany’s DAX (^GDAXI), rose in early Monday trading after an announcement that the United States and China reached an agreement to reduce and pause tariffs. This agreement followed weekend negotiations in Switzerland, resulting in both nations suspending most tariffs for a specified duration and agreeing to lower rates on future trade levies. The news boosted sentiment across the region's major indices, lifting multiple sectors in the early session.
The FTSE 100 edged higher, briefly rising close to a full percentage point at the market open. However, gains narrowed by mid-morning, with the index up only modestly as specific sectors underperformed. In contrast, indices such as the CAC 40 in France and Germany’s DAX experienced more robust upward movement, supported by optimism around international trade policy easing.
Pharmaceutical Stocks Drag on FTSE 100
Pharmaceutical companies listed on the London Stock Exchange (LSE) placed downward pressure on the FTSE 100 despite the broader market uplift. The sector responded to recent comments from the US administration regarding changes to drug pricing policy. The US president stated an intent to use executive authority to implement a reduction in certain medication prices for patients domestically.
Shares in major LSE-listed pharmaceutical firms including AstraZeneca (LSE:AZN), Hikma Pharmaceuticals (LSE:HIK), and GSK (LSE:GSK) declined during early trading. Each of these stocks experienced intraday losses following the announcement. The expected adjustments to drug pricing prompted a reassessment of revenue outlooks for pharmaceutical exporters to the United States, affecting their market performance.
Broader Market Momentum Outside the UK
Other major European indices displayed more consistent gains than the FTSE 100, with the DAX and CAC 40 both rising by more than a percentage point in early trading sessions. These indices were less affected by the US drug pricing development, and benefited more uniformly from the news of easing trade barriers between the US and China.
The pause in tariff impositions and agreed rate reductions were confirmed by US officials during Monday morning briefings, adding to the strength of global equity futures. This development appeared to support sectors such as manufacturing, technology, and automotive in continental Europe.
US Market Sentiment and Afternoon Outlook
Market expectations for a strong start on Wall Street also contributed to the positive sentiment in European trading. Futures contracts tied to major US indices pointed toward a stronger opening, further reinforcing equity valuations in Europe. Although the full impact of the tariff changes remains to be seen, the short-term lifting of trade-related tensions offered support to global markets.
The FTSE 100, FTSE 350, and FTSE AIM 100 Index were all influenced by the unfolding international developments. While the pharmaceutical segment within the FTSE 100 faced headwinds, broader sector strength helped keep the index in positive territory during the morning hours.
